Trial reportJournal of endocrinological investigation2012
Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
Trial report in Journal of endocrinological investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Mechanisms limiting the long-term anabolic effects of teriparatide (PTH 1-34) on bone.JBMR plus · 2026Review
- Early modification of blood glucose levels during teriparatide treatment in postmenopausal women with severe osteoporosis.Journal of endocrinological investigation · 2025Article
- Mass spectrometry-based metabolomics reveal the effects and potential mechanism of isochlorogenic acid A in MC3T3-E1 cells.Frontiers in molecular biosciences · 2025Article
- Study of the link between hemotopoietic and skeletal systems in patients attending a referral center for osteoporosis.Journal of endocrinological investigation · 2023Article
- Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics.International journal of molecular sciences · 2021Review
- Sclerostin and Vascular Pathophysiology.International journal of molecular sciences · 2020Review
- The influence of zoledronate and teriparatide on gamma delta T cells in mice.Journal of dental sciences · 2017Article
- New anabolic therapies for osteoporosis.Internal and emergency medicine · 2017Review
- The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.Journal of endocrinological investigation · 2017Article
- Review
- Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review.Journal of orthopaedic translation · 2016Review
- Fat and bone interactions.Current osteoporosis reports · 2014Review
- The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.Current osteoporosis reports · 2014Review
- Serum sclerostin levels following treatment with parathyroid hormone.Journal of endocrinological investigation · 2013Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was carried out in order to evaluate the effect of 18-month treatment with PTH (1-34) or PTH (1-84) on serum sclerostin levels in humans. SUBJECTS AND
methodsWe investigated 10 women with severe osteoporosis, previously treated with alendronate and 20 untreated osteoporotic women. Subjects with severe osteoporosis were randomly divided into 2 groups of 5 patients each; the first group was treated with 20 μg of PTH (1-34) and the second one with 100 μg of PTH (1-84) according to an open-label design. Fasting blood samples were collected at baseline and at 2, 4, and 24 h after hormone administration. The same protocol was followed at month 1, 6, 12, 18. Serum sclerostin levels were measured at each time point by a sandwich-type enzyme-linked immunosorbent assay.
resultsBasal serum sclerostin levels were not significantly different between patients previously treated with alendronate and those never treated. No significant acute change of serum sclerostin levels was observed after PTH administration. Fitting a mixed effect regression model, we found a significant time effect (p=0.0012) using the sclerostin level as the response variable and the month of drug administration as a single covariate. Treatment with both PTH molecules induced a monthly mean reduction of sclerostin levels of 0.1956 pmol/l.
conclusionsOur results indicate that long-term therapy with PTH (1-34) or PTH (1-84) in women with osteoporosis previously treated with alendronate is associated with a reduction in circulating sclerostin levels. This is a putative mechanism through which PTH performs its anabolic action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.